AKYNZEO

Peak

fosnetupitant and palonosetron

NDAINTRAVENOUSSOLUTION

Approved

Apr 2018

Lifecycle

Peak

Competitive Pressure

0/100

Mechanism of Action

Neurokinin 1 Antagonists

Pharmacologic Class:

Substance P/Neurokinin-1 Receptor Antagonist

Indications (8)

combination with dexamethasone in adults for the prevention of acute delayed nausea vomiting associated with initial repeat courses of highly emetogenic cancer chemotherapy repeat courses of cancer chemotherapy including but not limited to highly emetogenic chemotherapy

Loss of Exclusivity

LOE Date

Jun 2, 2037

136 months away

Patent Expiry

Jun 2, 2037

Patent Records (5)

Patent #	Expiry	Type	Use Code
9186357	Nov 18, 2030		U-2301
10828297	Dec 17, 2030		U-2301
11312698	May 23, 2032	SubstanceProduct	—
10208073	May 23, 2032		U-2301
10717721	May 23, 2032	Substance	—

Company

Ireland - Dublin

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers